• Subscribe
  • Magazine
  • Past Issues
  • Surveys
  • Industry Statistics
  • About Us
  • Members Only
  • Best Places to Work
    • Recent Quotes
    My Watchlist
    Indicators
    PennEnergy Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Fsd Pharma Inc Cl B (NQ: HUGE )

    0.3255 -0.0225 (-6.47%)
    Streaming Delayed Price Updated: 3:59 PM EDT, May 15, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 623,652
    Open 0.3460
    Bid (Size) 0.3300 (2)
    Ask (Size) 0.3500 (22)
    Prev. Close 0.3480
    Today's Range 0.3213 - 0.3500
    52wk Range 0.3140 - 1.680
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    TechMediaBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Marks Important Step in Advancing Lucid-21-302
    Via Investor Brand Network
    FSD Pharma Submits a Phase-1 Multiple Ascending Doses Clinical Trial Application for Lucid-21-302 (Lucid-MS) for Ethics Committee Review in Australia
    Via ACCESSWIRE

    Performance

    YTD
    -63.83%
    -63.83%
    1 Month
    -37.75%
    -37.75%
    3 Month
    -61.48%
    -61.48%
    6 Month
    -71.94%
    -71.94%
    1 Year
    -71.70%
    -71.70%

    More News

    Read More
    BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Enters Agreement to Conduct Clinical Trial to Assess Safety, Efficacy of unbuzzd(TM)
    Via Investor Brand Network
    FSD Pharma Signs Agreement with Applied Science and Performance Institute (ASPI) to Conduct a Clinical Trial in the United States to Assess the Safety and Efficacy of unbuzzd(TM) in an Induced State of Alcohol Intoxication
    Via ACCESSWIRE
    BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA:0K9A) Announces Celly Nu, Six+One Collaboration to Launch unbuzzd(TM)
    Via Investor Brand Network
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
    Via InvestorPlace
    FSD Pharma Provides Update from Celly Nu’s Partnership with Six+One for unbuzzd(TM)
    Via ACCESSWIRE
    BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA:0K9A) Issues Update on Celly Nu’s Pending Launch of unbuzzd(TM)
    Via Investor Brand Network
    FSD Pharma Provides Another Update on Celly Nu's Anticipated Launch of unbuzzd(TM)
    Via ACCESSWIRE
    BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA:0K9A) Announces Expansion of Investigative Pipeline
    Via Investor Brand Network
    Psychedelics Headlines: Dementia Prevention, Psychological Flexibility, Ancient Romans' Trips And More
    Via Benzinga
    FSD Pharma Expands Investigative Pipeline to Include Potential Weight Loss and Liver Health Formulations and Products
    Via ACCESSWIRE
    BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Releases Update on Celly Nu Investment
    Via Investor Brand Network
    FSD Pharma Provides Update on its Investment in Celly Nutrition Corp., a Company Launching a Product that can assist in Expediting Alcohol Metabolism and Faster Recovery from Alcohol Consumption
    Via ACCESSWIRE
    FSD Pharma Announces Filing of Year-End 2023 Results
    Via ACCESSWIRE
    Psychedelics Headlines: A Form Of Life, Treating Chronic Pain, Microdosing And More
    Via Benzinga
    InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Subsidiary Partners with iNGENu CRO to Initiate MS Clinical Study
    Via Investor Brand Network
    FSD Pharma Signs the Agreement With iNGENu CRO To Conduct a Clinical Study To Assess the Safety and Pharmacokinetics of Multiple Ascending Doses of Lucid-21-302 (Lucid-MS) in Healthy Adults
    Via ACCESSWIRE
    Psychedelics Headlines: Substitution Survey, Frank Herbert's Magic Mushrooms, Celestial Plans And News Review
    Via Benzinga
    FSD Pharma: A Compelling Value Proposition As UNBUZZD™ Positions To Dominate The Alcohol-Detox Functional Beverage Market
    Via AB Newswire
    FSD Pharma’s Stake In Functional Beverage, UNBUZZD™, Is A Transformational Asset…Here’s Why
    Via AB Newswire
    PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Takes First Step Toward Obtaining Permission for unbuzzd(TM) Phase-1b Clinical Trial
    Via Investor Brand Network
    FSD Pharma Submits a Phase-1b Clinical Trial Application for Ethics Committee for its Proprietary Beverage unbuzzd(TM)
    Via ACCESSWIRE
    PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Presents Positive Results on First-in-Human Phase 1 Study of Lucid-MS
    Via Investor Brand Network
    FSD Pharma Presents Positive Results on First-In-Human Phase-1 study of Lucid-21-302 (Lucid-MS) at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) 2024 Forum
    Via ACCESSWIRE
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.